P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.

• Yakir Moshe,
• Shai Levi,
• Miri Neeman,
• Roi Gat,
• Mor Levi,
• Nili Eilati,
• Tamir Shragai,
• May Basood,
• Yafit Segman,
• Yaeli Baron,
• Efrat Luttwak,
• Tsipora Neuman,
• Roy Vitkon,
• Moshe Mittelman,
• Irit Avivi

Affiliations

Yakir Moshe

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Shai Levi

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Miri Neeman

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Roi Gat

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Mor Levi

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Nili Eilati

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Tamir Shragai

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

May Basood

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Yafit Segman

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Yaeli Baron

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Efrat Luttwak

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Tsipora Neuman

2 Tel Aviv University, Sackler Faculty of medicine, Tel Aviv, Israel

Roy Vitkon

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel

Moshe Mittelman

2 Tel Aviv University, Sackler Faculty of medicine, Tel Aviv, Israel

Irit Avivi

1 Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv, Israel